Research Article
Detection of Soluble ED-A+ Fibronectin and Evaluation as Novel Serum Biomarker for Cardiac Tissue Remodeling
Table 1
Detailed patients’ characteristics.
| | Patients’ characteristics | |
| | Age (years) | 61 ± 13 | 114 |
| | NYHA class: I/II/III in % () | 33% ()/37% ()/30% () | 112 |
| | Heart failure genesis | Ischemic, % () | 39% () | 114 | | Dilated, % () | 34% () | | Hypertensive, % () | 27% () |
| | Body weight (kg) | 91 ± 18 | 106 |
| | Systolic blood pressure (mmHg) | 137 ± 22 | 110 |
| | Diastolic blood pressure (mmHg) | 86 ± 14 | 110 |
| | Comorbidities, % () | Hypertension | 82% () | 113 | | Hyperlipidemia | 55% () | 114 | | Diabetes mellitus | 29% () | 113 |
| | Comedication, % () | Statin | 57% () | 111 | | ACE-inhibitor | 78% () | 111 | | Beta-blocker | 97% () | 112 |
| | Laboratory values, mean ± SD | Creatinine (μmol/L) | 118 ± 76 | 112 | | Cholesterol (mmol/) | 5 ± 1.4 | 102 | | LDL-cholesterol (mmol/L) | 3 ± 1.2 | 102 | | BNP (pg/mL) | 1591 ± 796 | 100 | | Hemoglobin (g/dL) | 14 ± 1.9 | 114 |
|
|
